Company intelligence / Profile preview

ImmuXell Biotech

Shanghai, Shanghai, Chinaimmuxell.cn ↗

Ownership: Private
Development stage: Phase 1

Overview

ImmuXell Biotech is a clinical-stage company developing immune cell therapies, with its lead candidate IX001 currently in Phase 1 trials for advanced solid tumors driven by KRAS mutations. The company focuses on both personalized and universal TCR-based therapies to improve efficacy and accessibility of cell therapy for refractory malignancies. No published clinical results yet; the first trial began July 2024.[1][2][4][5]

Therapeutic areas: Oncology
Modalities: TCR-T cell therapySmall molecule drugsTCR fusion protein[1][2][5]
Industry: Biotech

Drug pipeline

2 assets

TCR-ICE

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed. Clinical collaboration with Shanghai Pudong Hospital as trial site/sponsor.[1]

Beyond the preview

Go deeper on ImmuXell Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuXell Biotech.

Explore the full profile